ArticleBritish journal of cancer2026
Metabolic dysregulation associated with core symptom cluster in lung cancer patients undergoing chemotherapy.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAdverse symptoms are the main reason for unexpected hospital admissions in lung cancer patients. The fatigue-pain-sleep disturbance symptom cluster is the core symptom cluster among those undergoing chemotherapy, significantly affecting the clinical outcomes of patients. The mechanisms behind the core symptom cluster haven't been well understood and may relate to metabolic disorders. Understanding the related mechanisms is crucial for symptom management and patient outcomes.
methodsOne hundred lung cancer patients undergoing chemotherapy were involved in this cross-sectional study. During their third to fifth chemotherapy, they were asked to complete questionnaires that evaluated the condition of fatigue, pain, and sleep disturbance. Patients were categorized into high, moderate, and low core symptom cluster groups using the K-means algorithm. Comparison was conducted on demographic data, symptoms, and symptom interference among groups. Plasma samples from patients were collected for untargeted metabolomics, and the differential metabolites among groups were identified. Pathway enrichment analysis was performed to understand the potential mechanism of the core symptom cluster. Trend analysis was conducted on the differential metabolites to identify the significant clusters of metabolites with similar variation among groups. Receiver Operating Characteristic curves were generated to evaluate the distinguish efficacy of the metabolites panel for the core symptom cluster.
resultsThe K-means algorithm categorized 100 patients into three groups based on core symptom cluster, including 46 in low, 35 in moderate, and 19 in high. Most of the cancer-related symptoms and symptom interference were increased progressively with the severity of the core symptom cluster. The metabolomic analysis identified 1,334 annotated metabolites. The high and moderate groups showed a higher similarity in metabolic profile, yet were distinct from the low group. Choline metabolism in cancer was the highest enrichment pathway in the Kyoto Encyclopedia of Genes and Genomes analysis. Trend analysis identified a panel of 24 metabolites that increased with core symptom cluster progression, distinguishing 87.8% of patients with moderate or high severity from those with low.
conclusionsThis study is the first to explore the metabolic profile associated with the core symptom cluster in lung cancer, revealing significant changes in the clinical phenotypes and metabolic disorders in patients with moderate to high core symptom cluster. Dysregulated choline metabolism emerged as a key signature within the broader metabolic disturbances linked to core symptom cluster. We identified a promising panel of metabolites for diagnosing the core symptom cluster, which are expected to serve as biomarkers in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.